EP2425874A3 - Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer - Google Patents

Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer Download PDF

Info

Publication number
EP2425874A3
EP2425874A3 EP11175046.9A EP11175046A EP2425874A3 EP 2425874 A3 EP2425874 A3 EP 2425874A3 EP 11175046 A EP11175046 A EP 11175046A EP 2425874 A3 EP2425874 A3 EP 2425874A3
Authority
EP
European Patent Office
Prior art keywords
cancer
vitamin
additional therapeutic
therapeutic agent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11175046.9A
Other languages
German (de)
French (fr)
Other versions
EP2425874A2 (en
Inventor
Alan H. Auerbach
Arie S. Belldegrun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Oncology Inc
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of EP2425874A2 publication Critical patent/EP2425874A2/en
Publication of EP2425874A3 publication Critical patent/EP2425874A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a vitamin D compound in combination with at least one additional therapeutic agent, such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising vitamin D compounds and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid, e.g., corticosteroid or more specifically, a glucocorticoid.
EP11175046.9A 2006-08-25 2007-08-23 Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer Withdrawn EP2425874A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93492406P 2006-08-25 2006-08-25
EP07837327A EP2063963A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP07837327.1 Division 2007-08-23

Publications (2)

Publication Number Publication Date
EP2425874A2 EP2425874A2 (en) 2012-03-07
EP2425874A3 true EP2425874A3 (en) 2013-05-15

Family

ID=39107444

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07837327A Withdrawn EP2063963A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
EP11175046.9A Withdrawn EP2425874A3 (en) 2006-08-25 2007-08-23 Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP07837327A Withdrawn EP2063963A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Country Status (9)

Country Link
EP (2) EP2063963A2 (en)
JP (1) JP2010501576A (en)
KR (1) KR20090060306A (en)
CN (1) CN101528309A (en)
AU (1) AU2007287099A1 (en)
CA (2) CA2661546A1 (en)
IL (1) IL197212A0 (en)
NO (1) NO20091191L (en)
WO (1) WO2008024485A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170434A (en) * 2009-01-27 2017-11-21 Berg Llc VITAMIN D3 AND ANALOGS OF THE SAME TO RELIEF SECONDARY EFFECTS ASSOCIATED WITH CHEMOTHERAPY. (Divisional 2011-0445)
SG176105A1 (en) 2009-06-26 2011-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
WO2011007208A1 (en) * 2009-07-16 2011-01-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds and methods for the treatment of cancer
CN103108871B (en) 2010-09-16 2014-09-10 诺华股份有限公司 17a-hydroxylase/c17,20-lyase inhibitors
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
MX359399B (en) 2011-04-28 2018-09-27 Novartis Ag 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS.
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
KR20210013342A (en) 2012-09-26 2021-02-03 아라곤 파마슈티컬스, 인코포레이티드 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
JOP20200097A1 (en) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
JP2016520572A (en) 2013-04-24 2016-07-14 ソーク インスティテュート フォー バイオロジカル スタディーズ Vitamin D receptor / SMAD genomic circuit regulates fibrosis
BR112015030518A2 (en) 2013-06-05 2017-08-29 Salk Inst For Biological Studi PHARMACEUTICAL COMPOSITION, USE OF ONE OR MORE VITAMIN D RECEPTOR (VDR) E AGONISTS, METHOD FOR REDUCING THE BIOLOGICAL ACTIVITY OF MOTIF C-X-C LIGAND 12 (CXCL12)
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies Use of bromodomain-containing protein 9 antagonists in combination with vitamin d receptor agonists in diabetes treatment
JOP20200076A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004917A2 (en) * 2004-06-30 2006-01-12 Bone Care International, Inc. Method of treating breast cancer using a combination of 1alpha, 24-dihydroxyvitamin d2 and a further chemotherapeutic agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
WO1987000834A1 (en) 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Novel vitamin d analogues
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
DE4101953A1 (en) 1991-01-19 1992-07-23 Schering Ag 23-OXA DERIVATIVES IN THE VITAMIN-D SERIES, METHOD FOR THE PRODUCTION THEREOF THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THE USE THEREOF AS MEDICINAL PRODUCTS
DE4141746A1 (en) 1991-12-13 1993-06-17 Schering Ag 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
ATE515265T1 (en) 1998-03-27 2011-07-15 Univ Oregon Health & Science VITAMIN D AND ITS ANALOGUES FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATIVE DISEASES
JP2003525254A (en) * 2000-03-02 2003-08-26 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション Combination chemotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004917A2 (en) * 2004-06-30 2006-01-12 Bone Care International, Inc. Method of treating breast cancer using a combination of 1alpha, 24-dihydroxyvitamin d2 and a further chemotherapeutic agent

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN G L ET AL: "Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.", BREAST CANCER RESEARCH AND TREATMENT MAY 2004, vol. 85, no. 1, May 2004 (2004-05-01), pages 53 - 63, XP002509087, ISSN: 0167-6806 *
COLSTON K W ET AL: "Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer.", ENDOCRINE-RELATED CANCER MAR 2002, vol. 9, no. 1, March 2002 (2002-03-01), pages 45 - 59, XP002509128, ISSN: 1351-0088 *
DANILENKO MICHAEL ET AL: "Enhancement by other compounds of the anti-cancer activity of vitamin D3 and its analogs", EXPERIMENTAL CELL RESEARCH, vol. 298, no. 2, 15 August 2004 (2004-08-15), pages 339 - 358, XP002509129, ISSN: 0014-4827 *
KOSHIZUKA K ET AL: "Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo", BREAST CANCER RESEARCH AND TREATMENT, SPRINGER, NEW YORK, NY, vol. 53, no. 2, 1 January 1999 (1999-01-01), pages 113 - 120, XP002356881, ISSN: 0167-6806 *
MASUDA SONOKO ET AL: "Promise of vitamin D analogues in the treatment of hyperproliferative conditions", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 4, April 2006 (2006-04-01), pages 797 - 808, XP002491460, ISSN: 1535-7163 *
MILLIKEN ET AL: "EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 229, no. 2, 18 November 2005 (2005-11-18), pages 205 - 215, XP027607812, ISSN: 0304-3835 *
SAUNDERS ET AL: "Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone", ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, vol. 6, no. 4, 1 August 1995 (1995-08-01), pages 562 - 569, XP002079311, ISSN: 0959-4973 *
VINK-VAN WIJNGAARDEN T ET AL: "INHIBITION OF BREAST CANCER CELL GROWTH BY COMBINED TREATMENT WITH VITAMIN D3 ANALOGUES AND TAMOXIFEN", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 54, 1 January 1994 (1994-01-01), pages 5711 - 5717, XP000937998 *

Also Published As

Publication number Publication date
CA2661546A1 (en) 2008-02-28
CA2838089A1 (en) 2008-02-28
EP2063963A2 (en) 2009-06-03
CN101528309A (en) 2009-09-09
IL197212A0 (en) 2009-12-24
EP2425874A2 (en) 2012-03-07
WO2008024485A2 (en) 2008-02-28
WO2008024485A3 (en) 2009-03-05
KR20090060306A (en) 2009-06-11
JP2010501576A (en) 2010-01-21
NO20091191L (en) 2009-03-23
AU2007287099A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
EP2478907A3 (en) Methods and compositions for treating cancer
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2008082602A3 (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2010068866A3 (en) Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006089150A3 (en) Antiangiogenic agents with aldesleukin
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
EP2460522A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP2481402A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
WO2007144152A3 (en) Extended step-down estrogen regimen
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
EP2281561A3 (en) Use of LCK inhibitors for treatment of immunologic diseases
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels

Legal Events

Date Code Title Description
AC Divisional application: reference to earlier application

Ref document number: 2063963

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/593 20060101ALI20130409BHEP

Ipc: A61K 31/573 20060101ALI20130409BHEP

Ipc: A61P 35/00 20060101AFI20130409BHEP

Ipc: A61K 31/592 20060101ALI20130409BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JANSSEN ONCOLOGY, INC.

17P Request for examination filed

Effective date: 20131114

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20131114

Extension state: RS

Payment date: 20131114

Extension state: BA

Payment date: 20131114

Extension state: AL

Payment date: 20131114

Extension state: HR

Payment date: 20131114

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180725

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220823